GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » Net Income

MNMD (Mind Medicine) Net Income : $-108.68 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Mind Medicine's Net Income for the three months ended in Dec. 2024 was $-34.74 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-108.68 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Mind Medicine's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.41.


Mind Medicine Net Income Historical Data

The historical data trend for Mind Medicine's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Net Income Chart

Mind Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Income
-33.94 -93.04 -56.80 -95.73 -108.68

Mind Medicine Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.86 -54.40 -5.85 -13.68 -34.74

Mind Medicine Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Mind Medicine's Net Income for the fiscal year that ended in Dec. 2024 is calculated as

Net Income(A: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-108.679+0+0+0
=-108.68

Mind Medicine's Net Income for the quarter that ended in Dec. 2024 is calculated as

Net Income(Q: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-34.741+0+0+0
=-34.74

Net Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-108.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mind Medicine  (NAS:MNMD) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Mind Medicine's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Mind Medicine Net Income Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Mind Medicine Business Description

Traded in Other Exchanges
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Executives
Mark Sullivan officer: Chief Legal Officer 1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054
Robert Barrow director, officer: Chief Executive Officer C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Dan Karlin officer: Chief Medical Officer C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Carrie Liao officer: VP, Controller&Acct Principal C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Schond L. Greenway officer: Chief Financial Officer C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
Carol A Vallone director 490 SUMMER STREET, MANCHESTER MA 01944
Andreas Krebs director 5 GIRALDA FARMS, MADISON NJ 07940
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Roger Crystal director 445 PARK AVE, 10TH FL., NEW YORK NY 10022
Cynthia W. Hu officer: Chief Legal Officer&Secretary 6440 WINDERMERE, NORTH BETHESDA MD 20852
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
Sarah Y Vinson director C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Stephen L Hurst director C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Miri Halperin Wernli director, officer: Executive President C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007